DiaDexus, Inc. announced today that the U.S. Patent and Trademark Office issued U.S. Patent No. 7,052,862, covering methods of diagnosing a patient's susceptibility for developing an atherosclerotic disease, including myocardial infarction and stroke, by analyzing a sample of a patient's blood for the presence and activity of Lipoprotein Associated Phospholipase A2 (Lp-PLA2) enzymatic activity to determine a patient's susceptibility to developing atherosclerotic disease, including stroke and myocardial infarction. Lp-PLA2, an enzyme associated with atherosclerotic plaque, was discovered by scientists at GlaxoSmithKline (GSK). This patent is one of several GSK patents to which diaDexus has an exclusive commercial diagnostic license.
Yahoo News
Simplifying Global Compliance
Recommended Products
EU MDR Compliance: A Checklist for Meeting Manufacturing, Safety and Performance Requirements
The FDAnews report EU MDR Compliance can help. Our editors have combed through the regulations, picking out the most minute compliance points and building them into a checklist of 200+ requirements you can use to confirm that you are satisfying all the EU mandates for device manufacturing.
Accelerating Generic Drug Development: The FDA’s New Plan for Increasing Generic Competition
Accelerating Generic Drug Development explains the FDA’s new policy and shows how to navigate the new pathway to approval.
Editor's Picks
J&J Enters Robotic Surgery Market
The companies entered into a cooperative agreement in May 2018 to combine J&J’s NeuWave system with the Monarch platform.
CDER’s Regulatory Modernization Will Peak in 2019, Woodcock Says
The center expects to have its proposed reorganization approved by HHS towards the end of FY 2019.
FDAnews Device Daily Bulletin
DIADEXUS ISSUED U.S. PATENT FOR LP-PLA2 ACTIVITY-BASED ATHEROSCLEROSIS DIAGNOSTIC TEST
May 31, 2006
